Literature DB >> 6834848

In vitro chemotherapy sensitivity testing of primary human colorectal carcinomas.

M V Agrez, M M Lieber.   

Abstract

The cells obtained from 138 tumor samples taken from 135 patients with colorectal malignancies were cultured in vitro in a soft agar colony formation assay similar to that of Salmon and colleagues [1]. Significant colony formation occurred for 63 (51%) of evaluable tumor cultures, 53 of which were also tested against chemotherapeutic agents in vitro. The median number of drugs tested per tumor was 15. Using 70% inhibition of colony formation as the criterion for significant drug-induced cytotoxicity, only 3/53 (6%) of the tumors were noted to be sensitive to any drug. When colony counts generated by initially plated small tumor cell aggregates were taken into account, 8/40 (20%) of the tumors were noted to be sensitive in vitro to one or more agents. Because of the low rate of drug sensitivity found with this in vitro assay, its current role in the prospective assignment of chemotherapeutic treatment for patients with colorectal carcinoma is somewhat limited.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6834848     DOI: 10.1002/jso.2930220413

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  3 in total

1.  Primary and metastatic liver lesions of clinical colorectal cancer differ in chemosensitivity.

Authors:  Y Maehara; Y Sakaguchi; Y Emi; T Kusumoto; S Kohnoe; M Mori; K Sugimachi
Journal:  Int J Colorectal Dis       Date:  1990-05       Impact factor: 2.571

2.  A clinical pilot study combining surgery with intraoperative pelvic hyperthermochemotherapy to prevent the local recurrence of rectal cancer.

Authors:  S Fujimoto; M Takahashi; F Endoh; R D Shrestha; M Kokubun; M Takai; K Okui
Journal:  Ann Surg       Date:  1991-01       Impact factor: 12.969

3.  Experiences with the human tumor colony-forming assay in gynecologic malignancies.

Authors:  G E Umbach; J Poethen; H von Matthiessen; H G Bender; U Koldovsky
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.